All In Biotech

Drug Trial Radar · NCT07903194

A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Phase III Clinical Study Evaluating the Efficacy and Safety of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Dec 21, 2027

Study completion Aug 29, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). A total of 210 patients aged 18 to 75 years with bilateral CRSwNP are planned to be enrolled and randomized in a 1:1 ratio to receive either MG-K10 or placebo. During the first 24 weeks, participants will receive MG-K10 or placebo; they will subsequently enter a 28-week maintenance treatment period, during which the original placebo group will switch to receive MG-K10, and blinding will be maintained in both groups. MG-K10 is administered subcutaneously once every 4 weeks. Both groups will receive mometasone furoate nasal spray as background therapy from the run-in period through the end of the study. Following the treatment period, participants will be followed up for 8 weeks up to Week 60. The co-primary endpoints are the changes from baseline in Nasal Polyp Score (NPS) and Nasal Congestion Score (NCS) at Week 24; other symptoms, quality of life, safety, pharmacokinetics, pharmacodynamics, and immunogenicity will also be evaluated.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • MG-K10Biological

    MG-K10 humanized monoclonal antibody injection administered via subcutaneous injection. During the first 24 weeks, the MG-K10 group receives an initial dose of 600 mg, followed by 300 mg every 4 weeks, for a total of 6 doses. At Week 24, the MG-K10 group receives 300 mg plus matching placebo, while the original placebo group receives an initial dose of 600 mg; thereafter, both groups receive 300 mg every 4 weeks, for a total of 7 doses during the maintenance treatment period.

  • PlaceboDrug

    Placebo matching MG-K10 administered via subcutaneous injection. During the first 24 weeks, the placebo group receives an initial dose of 4.0 mL, followed by 2.0 mL every 4 weeks, for a total of 6 doses. At Week 24, the MG-K10 group concurrently receives matching placebo 2.0 mL to maintain blinding.

  • Mometasone Furoate Nasal SprayDrug

    Mometasone furoate nasal spray administered as background therapy for all participants at 200 μg daily from the run-in period through study completion at Week 60: 2 actuations per nostril once daily, 50 μg per actuation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Bilateral Nasal Polyp Score (NPS)Time frame: Baseline and Week 24
  2. Change From Baseline in Nasal Congestion Score (NCS)Time frame: Baseline and Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.